Migraine Treatment Linked to Higher Miscarriage Risk Around Conception

A retrospective study published in JAMA Neurology suggests that anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies, used for migraine, are associated with an elevated risk of spontaneous abortion when exposed near conception or in early pregnancy. These findings highlight the need for further safety evaluation of these antibodies during pregnancy and advise clinicians to consider the limited evidence when discussing treatment with patients who may become pregnant.